drugset / Trial / NCT01697696

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

NCT01697696

Phase 3 Completed 511 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.

Timeline

Start
2012-10
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 15.6 ug Inhaled
Comparator Indacaterol Other / unclassified 75 ug Inhaled